Leaflet RANOLAZINA ATB 375mg prolonged-release tablets

Product code:
W69653002
Quantity:
60
Indicated for:
angina pectoris
Route of administration:
oral
Substance:
ranolazine (antihypertensive)
ATC
C01EB18 — Cardiovascular system | Other cardiac preparations
Ranolazine is a medication used to treat chronic angina, a condition characterized by chest pain caused by insufficient blood flow to the heart. It works by improving the efficiency of cardiac metabolism without significantly affecting heart rate or blood pressure.

The medication is taken orally, usually in extended-release tablet form, and should be used as directed by your doctor. It is important not to stop the treatment without consulting your doctor.

Side effects may include dizziness, nausea, constipation, or headache. In rare cases, severe adverse effects such as arrhythmias or allergic reactions may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as kidney or liver impairment, to ensure the safe use of ranolazine.

General data about RANOLAZINA ATB 375mg

Substance:
ranolazine
Date of latest medicines list:
01-06-2026
Product code:
W69653002
Concentration:
375mg
Pharmaceutical form:
prolonged-release tablets
Quantity:
60
Product type:
Generic medicine
Price:
95.90 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
ADAMED PHARMA S.A. - POLONIA
Holder:
ANTIBIOTICE S.A. - ROMANIA
Number:
14578/2022/02
Shelf life:
30 months

Pharmaceutical forms available for ranolazine

Concentrations available for ranolazine

  • 375mg
  • 500mg
  • 750mg